Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Bank of America Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price target lifted by investment analysts at Bank of America from $168.00 to $172.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s target price would indicate a potential upside of 12.37% from the stock’s previous close.

A number of other analysts have also issued reports on GILD. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. HSBC raised their target price on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Zacks Research lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Barclays decreased their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Finally, Royal Bank Of Canada increased their price target on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $159.63.

Gilead Sciences Trading Down 2.0%

Shares of GILD stock opened at $153.07 on Tuesday. The company’s fifty day simple moving average is $147.59 and its two-hundred day simple moving average is $137.39. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences has a 1 year low of $114.02 and a 1 year high of $160.51. The stock has a market capitalization of $189.80 billion, a price-to-earnings ratio of -57.33 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the prior year, the business posted $2.01 earnings per share. The business’s quarterly revenue was up 10.6% on a year-over-year basis. As a group, analysts anticipate that Gilead Sciences will post -0.47 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the chief financial officer directly owned 161,096 shares in the company, valued at $25,166,417.12. The trade was a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares in the company, valued at $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock valued at $15,877,860 in the last ninety days. 0.30% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

A number of large investors have recently modified their holdings of the business. Net Worth Advisory Group bought a new position in Gilead Sciences in the third quarter worth $229,000. Focused Alpha LLC boosted its holdings in shares of Gilead Sciences by 4.4% during the 3rd quarter. Focused Alpha LLC now owns 9,436 shares of the biopharmaceutical company’s stock valued at $1,407,000 after buying an additional 402 shares in the last quarter. Eagle Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 3.1% during the 3rd quarter. Eagle Wealth Advisors LLC now owns 3,730 shares of the biopharmaceutical company’s stock valued at $556,000 after buying an additional 111 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Gilead Sciences by 1.6% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 191,506 shares of the biopharmaceutical company’s stock valued at $28,544,000 after buying an additional 3,022 shares in the last quarter. Finally, CWA Asset Management Group LLC grew its position in shares of Gilead Sciences by 24.0% in the 3rd quarter. CWA Asset Management Group LLC now owns 78,639 shares of the biopharmaceutical company’s stock worth $11,721,000 after buying an additional 15,240 shares during the period. Institutional investors own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Ulcerative colitis trial success: Gilead reported positive Phase 2 SWIFT results for emvistegrast, an oral treatment for active ulcerative colitis. The data strengthen Gilead’s inflammatory bowel disease pipeline and could support a broader growth opportunity beyond its core HIV franchise. Gilead’s pill succeeds in mid-stage bowel disease trial
• Positive Sentiment: FDA approval momentum: Recent regulatory wins include approval of the Bixlenvo HIV regimen, a first-line label expansion for Trodelvy in metastatic triple-negative breast cancer, and approval of Hepcludex for chronic hepatitis delta. These decisions expand Gilead’s commercial opportunities across HIV, oncology and liver disease. How Investors Are Reacting To Gilead Sciences FDA Drug Approvals
• Positive Sentiment: Analyst and institutional support: Zacks upgraded Gilead to Rank #2, or “Buy,” citing improving earnings prospects. In addition, 43 exchange-traded funds added GILD shares, potentially providing incremental buying demand. Gilead rating upgrade to Buy
• Neutral Sentiment: Upcoming research disclosures: Gilead plans to present 28 studies at IDWeek 2026, covering HIV treatment, prevention and emerging antiviral programs. The event could provide additional catalysts, although the financial impact depends on the data and eventual commercialization.
• Negative Sentiment: Acquisition and profitability concerns: Investors remain focused on the cost of recent acquisitions, including Arcellx and Tubulis. Those deals have increased research expenses and contributed to a reported trailing 12-month loss, raising questions about near-term earnings and whether the acquisitions can generate sufficient returns. What Has Changed About Owning Gilead Stock?

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.